X4 Pharmaceuticals Inc (NASDAQ: XFOR) closed the day trading at $1.34 up 8.50% from the previous closing price of $1.24. On the day, 5639851 shares were traded.
Ratios:
For a better understanding of XFOR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.34 and its Current Ratio is at 5.34. In the meantime, Its Debt-to-Equity ratio is 1.14 whereas as Long-Term Debt/Eq ratio is at 1.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, B. Riley Securities on December 12, 2023, Downgraded its rating to Neutral and sets its target price to $1 from $3 previously.
On December 22, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $3.Cantor Fitzgerald initiated its Overweight rating on December 22, 2022, with a $3 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 11 ’24 when Mostafa Adam S. sold 52,500 shares for $0.88 per share. The transaction valued at 46,347 led to the insider holds 0 shares of the business.
Ragan Paula sold 49,678 shares of XFOR for $43,856 on Mar 11 ’24. The President and CEO now owns 765,068 shares after completing the transaction at $0.88 per share. On Mar 11 ’24, another insider, DiBiase Mary, who serves as the Chief Operating Officer of the company, sold 15,409 shares for $0.88 each. As a result, the insider received 13,591 and left with 291,752 shares of the company.
Stock Price History:
Over the past 52 weeks, XFOR has reached a high of $2.58, while it has fallen to a 52-week low of $0.57.
Shares Statistics:
A total of 167.43M shares are outstanding, with a floating share count of 122.08M. Insiders hold about 27.30% of the company’s shares, while institutions hold 35.96% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from X4 Pharmaceuticals, Inc. analysts. The consensus estimate for the next quarter is $37.58, with high estimates of $0.00 and low estimates of $0.02.
